HTx Project

EMSP joined forces to support EURORDIS and other partners of the HTx project that envisions a new generation of healthcare decision-making. The main aim of HTx is to create a framework for the Next Generation Health Technology Assessment (HTA) to support patient-centred, societally oriented, real-time decision-making on access to and reimbursement for health technologies throughout Europe.

HTx Project  cover image

People with MS have the possibility to influence the drivers of this research by interacting with project experts and making those tools fit their needs. This is an opportunity to shape the new decision-making models and decide the role patients can play in the future.

If you are a person with MS and would like to engage in the HTx project, please contact us via email at projects@emsp.org

Additional Resources:

HTx is a project that received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825162, commenced in January 2019 and lasting for 5 years.

Complex Decisions and Real World Evidence (RWE)

Healthcare professionals decide on the best therapies for their patients diagnosed with MS. They also determine in which moment and in which combination different treatments will offer the highest benefit.

However, clinical research doesn’t always answer the questions of healthcare professionals and decision-makers about standards of care or reimbursement of therapies.

The HTx project will test methods to combine all the data available from clinical research and real-world medical practice into artificial intelligence (AI) models, assessing therapeutic pathways on a personalised basis.

Such an AI-powered web application will allow healthcare professionals to identify the best therapeutic pathway for people with MS, based on their characteristics, in real-time, discussed with them during a consultation. This will also prove useful for health authorities that decide on the reimbursement of certain therapies. This tool is meant to assess the combination of MS treatments, that are most probable to prevent relapses for a person living with MS, based on personal characteristics.

Shared Decision Making in Health Technology Assessment

On 29 November 2022 we ensured meaningful patient involvement at the HTx workshop held under the title of “Shared Decision Making”. The objective of the event was to compile ways in which clinicians and patients can use Real-World Evidence (RWE) to explore expectations regarding the outcome(s) of treatment and to make shared decisions.

If you are a person with MS and would like to engage in the HTx project, please contact us via email at projects@emsp.org

Download or visit previous
EMSP annual reports

Select an option using the dropdown button then click on the button to proceed.

EMSP aisbl

Rue Auguste Lambiotte 144/8

1030 Brussels, Belgium

© 2021 EMSP. All rights reserved. Republication or redistribution of EMSP content, including by framing or similar means, is prohibited without the prior written consent of EMSP.